Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04438057 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19
A Phase 2 study of COVID-19, sponsored by Metro Infectious Disease Consultants.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
- 1
- Study location
NCT04438057: Completed Phase 2 study of COVID-19, sponsored by Metro Infectious Disease Consultants.
NCT04438057 is a Phase 2 study of COVID-19 that has completed, run by Metro Infectious Disease Consultants. The registered enrollment target is 103 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04438057, a Phase 2 study of COVID-19, has completed, sponsored by Metro Infectious Disease Consultants.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will provide investigational convalescent plasma for patients infected with the SARS-CoV-2 with mild to moderate symptoms who meet inclusion criteria as judged by physician evaluation.
Primary Outcome
a. Time to resolution of symptoms will be defined as time from randomization (day 0) to a successful outcome. c. A successful outcome is defined as symptom improvement of 3 numbers or down to zero on the memory aid for all symptoms noted.
Conditions Studied
Interventions
- BIOLOGICAL CCP
Study Locations (1)
Illinois
- Metro Infectious Disease Consultants - Burr Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2020-08-12 |
| Est. Completion | 2021-08-12 |
| Phase | Phase 2 |
What the finished NCT04438057 record still lists
NCT04438057 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which CCP is the first listed.
NCT04438057 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT04438057 about?
NCT04438057 is a clinical study titled "Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19". This study will provide investigational convalescent plasma for patients infected with the SARS-CoV-2 with mild to moderate symptoms who meet inclusion criteria as judged by physician evaluation.
What is the current status of trial NCT04438057?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2020-08-12. Estimated completion is 2021-08-12.
What conditions does trial NCT04438057 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04438057?
The interventions under investigation include: CCP (BIOLOGICAL).
Who is sponsoring clinical trial NCT04438057?
This trial is sponsored by Metro Infectious Disease Consultants, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04438057 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04438057's enrollment target sits among peer trials
103 197th of 298 higher than 101 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI